Iron bisglycinate Oral Tablet — Competitive Intelligence Brief

Iron bisglycinate Oral Tablet (Iron bisglycinate Oral Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron supplement. Area: Hematology.

phase 3 Iron supplement Iron (Fe2+) for hemoglobin and myoglobin synthesis Hematology Small molecule

Target snapshot

Iron bisglycinate Oral Tablet (Iron bisglycinate Oral Tablet) — Hatem AbuHashim. Iron bisglycinate provides bioavailable iron in a chelated form that is absorbed in the gastrointestinal tract to replenish iron stores and support hemoglobin synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Iron bisglycinate Oral Tablet TARGET	Iron bisglycinate Oral Tablet	Hatem AbuHashim	phase 3	Iron supplement	Iron (Fe2+) for hemoglobin and myoglobin synthesis
TOT'HEMA	TOT'HEMA	Laboratoire Innotech International	marketed	Iron supplement
elemental iron (NovaFerrum®)	elemental iron (NovaFerrum®)	University of Texas Southwestern Medical Center	marketed	Iron supplement	Iron (Fe2+/Fe3+) — cofactor for hemoglobin and myoglobin synthesis
Intravenous iron supplementation	Intravenous iron supplementation	University of Pecs	marketed	Iron supplement	Iron (Fe2+/Fe3+) for hemoglobin and myoglobin synthesis
Iron Sucrose Supplement	Iron Sucrose Supplement	Papageorgiou General Hospital	marketed	Iron supplement
ferrous fumarate with ascorbic acid	ferrous fumarate with ascorbic acid	Pharmacosmos A/S	marketed	Iron supplement with vitamin C enhancer
Treatment with oral sucrosomial iron	Treatment with oral sucrosomial iron	University of Rochester	marketed	Iron supplement (oral formulation)	Iron (Fe3+) absorption pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron supplement class)

1. Tanabe Pharma Corporation · 4 drugs in this class
2. Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri · 2 drugs in this class
3. Universidade Federal Fluminense · 2 drugs in this class
4. Clinica Fabia Mater · 1 drug in this class
5. GlaxoSmithKline · 1 drug in this class
6. Hatem AbuHashim · 1 drug in this class
7. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
8. Laboratoire Innotech International · 1 drug in this class
9. Lee's Pharmaceutical Limited · 1 drug in this class
10. Milton S. Hershey Medical Center · 1 drug in this class